Freestone Grove Partners’s Boston Scientific BSX Stock Holding History

Freestone Grove Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,327,239	Closed	-$127M	–	1001
2025 Q4	$127M	Buy	1,327,239 +1,254,840	+1,733%	+$123M	0.91%	4
2025 Q3	$7.07M	Buy	+72,399	New	+$7.5M	0.05%	317
2025 Q2	–	Sell	-3,187	Closed	-$322K	–	683
2025 Q1	$322K	Sell	3,187 -295,766	-99%	-$29.8M	﹤0.01%	465
2024 Q4	$26.7M	Buy	+298,953	New	+$26.3M	0.33%	104

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Freestone Grove Partners's BSX Position: Q1 2026 in Review

Freestone Grove Partners sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 1,327,239 shares — an estimated $127M sold.

Freestone Grove Partners first reported a position in BSX in Q4 2024 and held it in 4 quarters. The position peaked at $127M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Freestone Grove Partners reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Freestone Grove Partners sold 1,327,239 Boston Scientific shares in Q1 2026, an estimated $127M.
Freestone Grove Partners first reported a position in Boston Scientific in Q4 2024 and held it in 4 quarters.
Freestone Grove Partners's Boston Scientific position peaked at $127M in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.